WO2000078753A1 - Process for the preparation of paroxetine and structurally related compounds - Google Patents
Process for the preparation of paroxetine and structurally related compounds Download PDFInfo
- Publication number
- WO2000078753A1 WO2000078753A1 PCT/GB2000/002455 GB0002455W WO0078753A1 WO 2000078753 A1 WO2000078753 A1 WO 2000078753A1 GB 0002455 W GB0002455 W GB 0002455W WO 0078753 A1 WO0078753 A1 WO 0078753A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- toluene
- solution
- compound
- equivalents
- Prior art date
Links
- 0 *OC(*(CC1)CC(COc(cc2)cc3c2OCO3)C1c(cc1)ccc1F)=O Chemical compound *OC(*(CC1)CC(COc(cc2)cc3c2OCO3)C1c(cc1)ccc1F)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Definitions
- the present invention relates to new processes for preparing pharmaceutically active compounds and intermediates therefor.
- R >2 is typically an alkyl, aryl or arylalkyl group.
- EP-0 810 225 describes a preparation of paroxetine in which the N-ethoxycarbonyl derivative is hydrolysed by heating at 90°C in ethanol/water with KOH for 3 days.
- the phenyl carbamate of a paroxetine analogue is hydrolysed at 130-140°C in toluene with KOH and ethyleneglycol monomethylether for four hours.
- EP 0 223 403 an earlier application of the present applicant, treats the N- phenoxycarbonyl derivative in toluene with KOH for two hours at reflux. Serious difficulties have been encountered in attempts to scale up this process. Even with vigorous agitation during reflux, long reaction times and incomplete reactions were encountered. Whilst acceptable on a laboratory scale, these processes are not applicable to implementation on an industrial scale.
- the present invention provides a process for the preparation of a paroxetine derivative of formula (1):
- R is a substituted phenyl group, preferably 3,4-methylenedioxyphenyl; by hydrolysing a carbamate of formula (2)
- R 2 is a C ⁇ -6 alkyl group, a C 3-6 cycloalkyl group, aralkyl group, phenyl or substituted phenyl group and R 1 is as defined above.
- the process comprises formation of a finely divided, e.g.sand-like, complex of potassium hydroxide and the carbamate derivative at a temperature well below the reflux temperature of toluene (110.6°C), for example at between 70 and 90°C.
- the complex is easily stirrable and reacts quickly and cleanly to form paroxetine. Once formed, the well- stirred mixture is heated steadily to reflux temperature to complete the reaction, normally within one hour.
- the sand-like complex of potassium hydroxide and carbamate derivative may be prepared by heating a mixture of the carbamate and potassium hydroxide, preferably in a finely divided form such as a flake, to a suitable temperature, and then discontinuing the heating while stirring vigorously.
- a suitable temperature is between 70 and 90°C, whilst for other carbamates it may be determined by simple experiment.
- the solvent is toluene.
- potassium hydroxide flake contains 10-20% water, and other sources of water may well be present in the reaction. We have found that the hydrolysis reaction is more rapid and gives lower levels of side-reaction products in the absence of excess water. These conditions may be achieved by modifying the apparatus to a Dean and Stark or similar configuration and carrying out the reaction in a dehydrating medium, so that water is removed during the reaction.
- the dehydrating medium is toluene and excess water is removed by azeotropic distillation, preferably until the water content is below 30%, more preferably less than 20%, more preferably still below 10% by weight with respect to the weight of compound of formula (2).
- concentration of carbamate is critical. Low concentration are undesirable because of vessel occupancy and other overheads, whereas high concentrations result in incomplete reactions. Suitable concentrations on a weight/weight basis are between 4 and 10 %, preferably between 5.5 and 9%, most preferably between 6.5 and 8.0%.
- Potassium phenate is a by-product of the above process and must be removed.
- the aqueous wash described in EP-0 223 403 has been found to be unsatisfactory on an industrial scale, even if high volumes of water are used, which is, of course, undesirable for efficient plant utilisation. If optimal reaction conditions have been applied to the reaction with KOH, most of the potassium phenate can be removed by filtration as a crystalline precipitate.
- the prior art ambient temperature aqueous wash is replaced by a high temperature wash, using water which has been pre-heated, preferably to between 60 and 95°C, more preferably between 70 and 80 °C.
- the volume of water used is preferably between Vi and V 20 of the volume of toluene used in the reaction, more preferably between V 3 and V 5 . It has been found that this procedure achieves successful removal of potassium phenate, contrary to expectations in view of the large excess of potassium hydroxide used in the reaction. Such concentrated solutions of KOH at elevated temperatures would ordinarily be expected to be very aggressive and cause degradation of the desired product.
- paroxetine derivative product may be isolated in a sufficiently pure form from the toluene solution by evaporation, from which any of the known salts may be formed.
- the co-solvent is an alcohol, ketone, ester or chlorinated hydrocarbon. More preferably, it is an alcohol, most preferably ethanol, typically IMS.
- the co- solvent is added to the reaction solvent after the aqueous wash, but before cooling to ambient temperature.
- the co-solvent is added at between 50 and 60°C, typically at about 55°C.
- a volume equivalent to between V 20 and V 60 of the volume of the toluene solution is added, preferably between V 30 and V 40 .
- the solution is suitably cooled to between 10°C and 30°C, preferably between 15 and 25°C and seeds of the desired paroxetine hydrochloride crystalline form, such as the hemihydrate, are added (preferably in an amount of between 0.05 and 1%, more preferably about 0.1% by weight).
- the solution is acidified with hydrochloric acid, suitably aqueous concentrated hydrochloric acid, with vigorous stirring.
- hydrochloric acid suitably aqueous concentrated hydrochloric acid, with vigorous stirring.
- an amount of hydrochloric acid in excess of the theoretical amount required is added, typically between 1.1 and 2 equivalents, preferably between 1.3 and 1.8 equivalents, more preferably between 1.5 and 1.7 equivalents.
- the acid is added very rapidly with vigorous stirring.
- the mixture is preferably stirred for at least 30 minutes to complete crystallisation, following which, the temperature of the mixture may be reduced to 1-5°C for final crystallisation.
- catechol impurities are formed during acidification from hydrolysis intermediates and are particularly problematic, being difficult to remove by crystallisation and resulting in coloured products. These products are typically caused by trace quantities of alcohols from earlier processing stages, or from plant washing protocols or by impurities in the solvents.
- the production of catechols can be reduced by first rinsing the reaction vessel with toluene and by washing the toluene phase with water.
- an aqueous alkali wash typically sodium hydroxide
- this alkali wash is carried out at above ambient temperature, preferably in the range 40-60°C, more preferably about 50°C.
- sodium hydroxide is available as a 50% by weight aqueous solution and so it is convenient to add heated water first, typically between 1/3 and l A of the volume of toluene, followed by an addition of 50% sodium hydroxide solution, preferably between 5 and 10 equivalents, more preferably between 6 and 8 equivalents.
- the previous treatment with co-solvent, seed and acid is repeated to isolate a purified paroxetine hemihydrate product.
- the product may be subjected to a further purification by recrystallisation from propan-2-ol containing between 1% and 10% water, preferably between 2% and 4%. Between 5 and 10 parts of propan-2-ol are used relative to the weight of solid product, preferably between 7 and 8 parts. It has been found that a greatly improved form of product is obtained if the crystallisation is initiated at a relatively high temperature. Accordingly, the propan-2-ol solution is preferably cooled from reflux to between 50 and 60°C, more preferably in the region of 55°C, and the mixture seeded (1-5% by weight of expected product is used as seed). The mixture is then allowed to crystallise for 2-4 hours before gradually cooling to 0°C. After a further period of stirring (2-4 hours) the product is filtered, washed with aqueous propan-2-ol and dried
- the process of this invention may be used to prepare active compounds described in US- A-3912743 and US-A-4007196, and preferably to prepare paroxetine hydrochloride hemihydrate.
- hydrochloride hemihydrate solvated, non- crystalline, or anhydrate hydrochloride salts or paroxetine salts with other acids may be isolated according to previously disclosed procedures.
- Paroxetine is preferably obtained as or converted to the hydrochloride salt and most preferably the hemihydrate of that salt, as described in EP-A-0223403.
- the present invention includes within its scope the compound paroxetine, particularly paroxetine hydrochloride, especially as the hemihydrate, when obtained via any aspect of this invention, and any novel intermediates resulting from the described procedures.
- Paroxetine is the (-)-trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxy- phenoxymethyl)-piperidine.
- optical resolution may be carried out prior to coupling with the phenol.
- resolution may be carried out at other stages, such as after deprotection of the piperidine nitrogen.
- Example 2 illustrates resolution of the N-deprotected compound.
- Paroxetine obtained using this invention may be formulated for therapy in the dosage forms described in EP-A-0223403 or WO96/24595, either as solid formulations or as solutions for oral or parenteral use.
- paroxetine especially paroxetine hydrochloride, obtained using this invention
- PMS pre-menstrual syndrome
- adolescent depression trichotillomania
- dysthymia substance abuse
- compositions for treatment or prophylaxis of the Disorders comprising paroxetine or paroxetine hydrochloride obtained using the process of this invention and a pharmaceutically acceptable carrier,
- paroxetine or paroxetine hydrochloride obtained using the process of this invention to manufacture a medicament for the treatment or prophylaxis of the Disorders
- a method of treating the Disorders which comprises administering an effective or prophylactic amount of paroxetine or paroxetine hydrochloride obtained using the process of this invention to a person suffering from one or more of the disorders.
- the contents of the reactor were cooled to 55°C, treated with industrial methylated spirit (IMS) (40 litres), cooled further to 20°C, and seeded with paroxetine hydrochloride hemihydrate (60 g).
- Concentrated hydrochloric acid 28 litres was added with vigorous stirring, and the stirring maintained for a further 30 minutes.
- Water 420 litres and 50% aqueous sodium hydroxide solution (112 kg) was added, and the mixture heated to 50°C.
- the vessel contents were thoroughly sti ⁇ ed, allowed to settle, and the aquous layer discharged to waste.
- the toluene layer was then washed with water (400 litres) and cooled to 20°C.
- the crystalline product from toluene/IMS was filtered and then dissolved in propan-2-ol (570 litres) at 65°C. Water was added (15 litres) followed by seeds of paroxetine hydrochloride hemihydrate (60 g). The solution was then cooled to 55°C and stirred for 3 hours at this temperature before being cooled to 0-5°C and stirred for a further 2 hours. The slurry was filtered and the solid washed with aqueous isopropyl alcohol and dried under vacuum at 35°C to give paroxetine hydrochloride hemihydrate free of catechol impurities.
- Paroxetine free base is liberated from the (-) trans 4-(4'-fluoro-phenyl)-3-(3",4"- methylenedioxyphenoxymethyl) piperidine di-p-toluoyl or dibenzoyl tartrate salt by stirring in a mixture of toluene and dilute aqueous sodium hydroxide. The phases are separated and the toluene phase washed with water. Concentrated aqueous hydrochloric acid is then added and the crystalline precipitate collected by filtration and dried.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00940621A EP1187830A1 (en) | 1999-06-22 | 2000-06-22 | Process for the preparation of paroxetine and structurally related compounds |
JP2001504919A JP2003502422A (en) | 1999-06-22 | 2000-06-22 | Preparation of paroxetine and structurally related compounds |
AU55532/00A AU5553200A (en) | 1999-06-22 | 2000-06-22 | Process for the preparation of paroxetine and structurally related compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9914583.1 | 1999-06-22 | ||
GBGB9914583.1A GB9914583D0 (en) | 1999-06-22 | 1999-06-22 | Novel process |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000078753A1 true WO2000078753A1 (en) | 2000-12-28 |
Family
ID=10855841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/002455 WO2000078753A1 (en) | 1999-06-22 | 2000-06-22 | Process for the preparation of paroxetine and structurally related compounds |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1187830A1 (en) |
JP (1) | JP2003502422A (en) |
AU (1) | AU5553200A (en) |
GB (1) | GB9914583D0 (en) |
WO (1) | WO2000078753A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL1017421C2 (en) * | 2001-02-21 | 2002-01-15 | Synthon Bv | Process for the production of paroxetine. |
EP1482939A1 (en) * | 2002-02-22 | 2004-12-08 | Teva Pharmaceutical Industries Ltd. | Preparation of paroxetine involving novel intermediates |
US6956121B2 (en) | 2002-03-01 | 2005-10-18 | Teva Pharmaceutical Industries Ltd. | Preparation of paroxetine involving novel intermediates |
WO2007015262A2 (en) * | 2005-04-25 | 2007-02-08 | Sun Pharmaceutical Industries Limited | A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
JP2010260826A (en) * | 2009-05-08 | 2010-11-18 | Sumitomo Chemical Co Ltd | Method of manufacturing paroxetine hydrochloride semihydrate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3912743A (en) * | 1973-01-30 | 1975-10-14 | Ferrosan As | 4-Phenylpiperidine compounds |
EP0152273A2 (en) * | 1984-02-07 | 1985-08-21 | A/S Ferrosan | A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use |
EP0190496A2 (en) * | 1984-12-13 | 1986-08-13 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
EP0223403A2 (en) * | 1985-10-25 | 1987-05-27 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
WO1996024595A1 (en) * | 1995-02-06 | 1996-08-15 | Smithkline Beecham Plc | New forms of paroxetin hydrochloride |
EP0810225A1 (en) * | 1996-05-31 | 1997-12-03 | Asahi Glass Company Ltd. | Process for producing paroxetine |
-
1999
- 1999-06-22 GB GBGB9914583.1A patent/GB9914583D0/en not_active Ceased
-
2000
- 2000-06-22 EP EP00940621A patent/EP1187830A1/en not_active Withdrawn
- 2000-06-22 WO PCT/GB2000/002455 patent/WO2000078753A1/en not_active Application Discontinuation
- 2000-06-22 AU AU55532/00A patent/AU5553200A/en not_active Abandoned
- 2000-06-22 JP JP2001504919A patent/JP2003502422A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3912743A (en) * | 1973-01-30 | 1975-10-14 | Ferrosan As | 4-Phenylpiperidine compounds |
US4007196A (en) * | 1973-01-30 | 1977-02-08 | A/S Ferrosan | 4-Phenylpiperidine compounds |
EP0152273A2 (en) * | 1984-02-07 | 1985-08-21 | A/S Ferrosan | A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use |
EP0190496A2 (en) * | 1984-12-13 | 1986-08-13 | Beecham Group Plc | Piperidine derivatives having a gastro-intestinal activity |
EP0223403A2 (en) * | 1985-10-25 | 1987-05-27 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
WO1996024595A1 (en) * | 1995-02-06 | 1996-08-15 | Smithkline Beecham Plc | New forms of paroxetin hydrochloride |
EP0810225A1 (en) * | 1996-05-31 | 1997-12-03 | Asahi Glass Company Ltd. | Process for producing paroxetine |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL1017421C2 (en) * | 2001-02-21 | 2002-01-15 | Synthon Bv | Process for the production of paroxetine. |
WO2002066466A1 (en) * | 2001-02-21 | 2002-08-29 | Synthon B.V. | Process to produce paroxetine |
US6686473B2 (en) | 2001-02-21 | 2004-02-03 | Synthon Bct Technologies, Llc | Process for the production of paroxetine |
EP1482939A1 (en) * | 2002-02-22 | 2004-12-08 | Teva Pharmaceutical Industries Ltd. | Preparation of paroxetine involving novel intermediates |
EP1482939A4 (en) * | 2002-02-22 | 2005-10-12 | Teva Pharma | Preparation of paroxetine involving novel intermediates |
US6956121B2 (en) | 2002-03-01 | 2005-10-18 | Teva Pharmaceutical Industries Ltd. | Preparation of paroxetine involving novel intermediates |
WO2007015262A2 (en) * | 2005-04-25 | 2007-02-08 | Sun Pharmaceutical Industries Limited | A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine |
WO2007015262A3 (en) * | 2005-04-25 | 2009-05-07 | Sun Pharmaceutical Ind Ltd | A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine |
Also Published As
Publication number | Publication date |
---|---|
GB9914583D0 (en) | 1999-08-25 |
AU5553200A (en) | 2001-01-09 |
JP2003502422A (en) | 2003-01-21 |
EP1187830A1 (en) | 2002-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG61323B2 (en) | Piperidine derivatives, its preparation and its use as medicaments | |
KR20000064387A (en) | Method and intermediate for preparing 1-benzyl-4-((5,6-dimethoxy-1-indanon) -2-yl) methylpiperidine | |
US20040087795A1 (en) | Novel processes for the preparation of 4-phenylpiperidine derivatives | |
WO2000078753A1 (en) | Process for the preparation of paroxetine and structurally related compounds | |
US20040147754A1 (en) | Novel process | |
AU2001278094B2 (en) | Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride | |
WO2001029032A1 (en) | Process for the preparation of paroxetine | |
US20040138460A1 (en) | Process for the production of paroxetine | |
EP0823907B1 (en) | PROCESS FOR PREPARING (-)-TRANS-N-p-FLUOROBENZOYLMETHYL-4-(p-FLUOROPHENYL)-3-[[3,4-(METHYLENEDIOXY)PHENOXY]METHYL]-PIPERIDINE | |
WO2001029031A1 (en) | Process for the preparation of paroxetine | |
JP2002531451A (en) | Preparation of paroxetine hydrochloride | |
EP1280775A1 (en) | TOSYLATE SALTS OF 4-(p-FLUOROPHENYL)-PIPERIDINE-3-CARBINOLS | |
OA11635A (en) | Process for the preparation of paroxetine hydrochloride. | |
US20030004352A1 (en) | Novel process | |
US20030187269A1 (en) | Novel process | |
WO2001004113A2 (en) | Process for the preparation of paroxetine and synthetic intermeditates thereof | |
EP1135383B1 (en) | Mixed paroxetine propan-2-ol solvates | |
EP1140911A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
EP1140910A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
JP2000198779A (en) | Purification of 3-alkylflavanol derivative | |
EP1178962A1 (en) | Process for the preparation of paroxetine acetate and analogues thereof | |
WO2000039123A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues | |
KR19990008135A (en) | Method for preparing (-)-trans-ene-pi-fluorobenzoylmethyl-4- (pi-fluorophenyl) -3-[[3,4- (methylenedioxy) phenoxy] methyl] -piperidine | |
WO2001012623A1 (en) | Process for the preparation of paroxetine hydrochloride | |
CZ20033024A3 (en) | Process for preparing and purifying tramadol and tramadol-hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000940621 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 504919 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000940621 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000940621 Country of ref document: EP |